Background and Study Aims: Patients with advanced, unresectable esophageal carcinoma have an extremely poor prognosis, with dysphagia being the major problem. The aim of this prospective pilot study was to evaluate the efficacy of local injections of mitomycin adsorbed onto activated carbon particles (MMC-CH) in advanced unresectable esophageal squamous-cell carcinoma. The primary outcome parameter was survival time; secondary parameters were dysphagia and quality of life.
Patients and Methods: Ten consecutive patients with stage IV esophageal carcinoma (age: median 58, range 32 - 78), median tumor length 11 cm (range 5 - 15) received four weekly injections of 15 mg (10 ml) MMC-CH into the endoscopically visualized tumor, via a 5-mm sclerotherapy needle. The tumor stage, symptom score, and quality of life (measured using the Karnofsky index) were assessed before and after therapy and every 2 months thereafter.
Results: The median survival time after MMC-CH therapy was 16 weeks (95 % CI, 11.7 to 20.4). Dysphagia was reduced (P < 0.001) in parallel with the reduction in the tumor mass (r = 0.82, P = 0.01). The Karnofsky index (P < 0.01) also improved after MMC-CH treatment. MMC-CH was well tolerated, and no side effects were observed.
Conclusions: Endoluminal MMC-CH therapy appears to be an effective, inexpensive, and well-tolerated treatment for unresectable advanced squamous-cell esophageal carcinoma.
References
-
1
Lambert R.
An overview of the management of cancer of the esophagus.
Gastrointest Endosc Clin N Am.
1998;
8
415-434
-
2
Lambert R.
Treatment of esophagogastric tumors.
Endoscopy.
2003;
35
118-126
-
3
Makuuchi H, Machimura T, Soh Y. et al .
Endoscopic mucosectomy for mucosal carcinomas in the esophagus.
Jpn J Gastroenterol Surg.
1991;
24
2599-2603
-
4
Goseki N, Koike M, Yoshida M.
Histopathologic characteristics of early stage esophageal carcinoma: a comparative study with gastric carcinoma.
Cancer.
1992;
69
1088-1093
-
5
Nagawara H, Kaizaki S, Seto Y. et al .
The relationship of macroscopic shape of superficial esophageal carcinoma to depth of invasion and regional lymph node metastasis.
Cancer.
1995;
75
1061-1064
-
6
Hagiwara A, Ahn T, Ueda T. et al .
Anticancer agents adsorbed by activated carbon particles: a new form of dosage-enhancing efficacy on lymph-nodal metastases.
Anticancer Res.
1986;
6
1005-1008
-
7
Hagiwara A, Takahashi T, Ueda T. et al .
Activated carbon particles as anti-cancer drug carrier into regional lymph nodes.
Anti-Cancer Drug Design.
1987;
1
313-321
-
8
Hagiwara A, Takahashi T, Ueda T. et al .
Enhanced therapeutic efficacy on lymph node metastasis by the use of peplomycin adsorbed on small activated carbon particles.
Anticancer Research.
1988;
8
287-290
-
9
Hagiwara A, Takahashi T, Kojima O. et al .
Endoscopic local injection of a new drug-delivery format of peplomycin for superficial esophageal cancer: a pilot study.
Gastroenterology.
1993;
104
1037-1043
-
10
Karnofsky D A, Abelman W H, Craver L F. et al .
The use of nitrogen mustards in the palliative treatment of carcinoma.
Cancer.
1948;
1
634-656
-
11 Karnofsky D A, Burchenal H. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, (ed) Evaluation of chemotherapeutic agents. New York; Columbia University Press 1949: 191-205
-
12 Klein J P, Moschberger M L. Survival analysis: techniques for censored and truncated data. New York; Springer 1997
-
13
Chung S CS, Leong H T, Leung J WC. et al .
Palliation of malignant esophageal obstruction by endoscopic alcohol injection.
Endoscopy.
1994;
26
275-277
-
14
Angelini G, Pasini A F, Ederle A. et al .
Nd: YAG laser versus polidocanol injection for palliation of esophageal malignancy: a prospective, randomized study.
Gastrointest Endosc.
1991;
37
607-610
-
15
Mayoral W, Fleischer D, Salcedo J. et al .
Nonmalignant obstruction is a common problem with metal stents in the treatment of esophageal cancer.
Gastrointest Endosc.
2000;
51
556-559
-
16
Neuhaus H, Hoffmann W, Dittler H J. et al .
Implantation of self-expanding esophageal metal stents for palliation of malignant dysphagia.
Endoscopy.
1992;
24
405-410
M. Ortner, M. D.
Division de Gastro-entérologie et Hépatologie
BH-10N, Centre Hospitalier Universitaire Vaudois · CH-1011 CHUV-Lausanne · Switzerland
Fax: +41-21-3140707 ·
eMail: Maria-Anna.Ortner@hospvd.ch
